Table 3.
Top GSEA results at each stage of addiction
| Name | Size | Abs NES | Comparison |
|---|---|---|---|
| Exposure | |||
| BERENJENO_TRANSFORMED_BY_RHOA_UP | 19 | 1.7849 | MRA0 |
| CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP | 15 | 1.7717 | MRE0 |
| MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN | 38 | 1.5766 | FRE0 |
| MIKKELSEN_ES_ICP_WITH_H3K4ME3 | 19 | 1.5370 | MPA0 |
| IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR | 17 | 1.5305 | FPA0 |
| BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS | 34 | 1.5283 | FPA0 |
| KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP | 26 | 1.5254 | MPA0 |
| REACTOME_ADAPTIVE_IMMUNE_SYSTEM | 19 | 1.5120 | MPE0 |
| FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN | 19 | 1.5098 | FRA0 |
| MULLIGHAN_NPM1_SIGNATURE_3_UP | 15 | 1.5025 | FPA0 |
| Withdrawal | |||
| BROWNE_HCMV_INFECTION_48HR_DN | 18 | 1.6251 | FPE8 |
| LEE_BMP2_TARGETS_UP | 21 | 1.5897 | FRA8 |
| LEE_BMP2_TARGETS_UP | 21 | 1.5700 | MPA8 |
| CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1 | 17 | 1.5666 | MRA8 |
| GENTILE_UV_HIGH_DOSE_DN | 17 | 1.5531 | FPE8 |
| KIM_ALL_DISORDERS_CALB1_CORR_UP | 21 | 1.5507 | MPA8 |
| MASSARWEH_TAMOXIFEN_RESISTANCE_UP | 20 | 1.5442 | FRE8 |
| NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON | 15 | 1.5416 | FPE8 |
| ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN | 20 | 1.5379 | FRE8 |
| GEORGES_TARGETS_OF_MIR192_AND_MIR215 | 31 | 1.5357 | MPA8 |
| ROME_INSULIN_TARGETS_IN_MUSCLE_UP | 18 | 1.5235 | MPA8 |
| SENESE_HDAC3_TARGETS_DN | 20 | 1.5230 | MPA8 |
| REACTOME_DEVELOPMENTAL_BIOLOGY | 20 | 1.5119 | FRA8 |
| WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D | 31 | 1.5118 | MPA8 |
| WONG_ADULT_TISSUE_STEM_MODULE | 33 | 1.5110 | MPA8 |
| SANSOM_APC_TARGETS_DN | 19 | 1.5100 | MPA8 |
| SCHLOSSER_SERUM_RESPONSE_DN | 25 | 1.5066 | MRE8 |
| MARTENS_TRETINOIN_RESPONSE_DN | 18 | 1.5031 | MPA8 |
| Abstinence | |||
| PUJANA_ATM_PCC_NETWORK | 52 | 1.7171 | MRE21 |
| PUJANA_BRCA1_PCC_NETWORK | 61 | 1.7011 | MRE21 |
| RICKMAN_METASTASIS_UP | 15 | 1.6639 | MPA21 |
| MILI_PSEUDOPODIA_HAPTOTAXIS_DN | 21 | 1.6363 | MRE21 |
| SWEET_LUNG_CANCER_KRAS_DN | 16 | 1.6335 | FPE21 |
| MULLIGHAN_MLL_SIGNATURE_2_DN | 16 | 1.6196 | MRE21 |
| BLALOCK_ALZHEIMERS_DISEASE_UP | 70 | 1.6024 | MRE21 |
| MATSUDA_NATURAL_KILLER_DIFFERENTIATION | 22 | 1.6012 | MRE21 |
| CHEN_METABOLIC_SYNDROM_NETWORK | 37 | 1.5881 | MPA21 |
| SENESE_HDAC3_TARGETS_DN | 20 | 1.5805 | FRE21 |
| PILON_KLF1_TARGETS_UP | 20 | 1.5713 | MRE21 |
| REACTOME_DEVELOPMENTAL_BIOLOGY | 20 | 1.5662 | MRE21 |
| PUJANA_CHEK2_PCC_NETWORK | 28 | 1.5608 | MRE21 |
| GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP | 48 | 1.5584 | MRE21 |
| STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN | 17 | 1.5529 | MRE21 |
| ONKEN_UVEAL_MELANOMA_UP | 28 | 1.5457 | MRE21 |
| BAKKER_FOXO3_TARGETS_DN | 25 | 1.5455 | MRE21 |
| WONG_ADULT_TISSUE_STEM_MODULE | 33 | 1.5314 | MRE21 |
| PHONG_TNF_RESPONSE_NOT_VIA_P38 | 16 | 1.5189 | MPA21 |
| LIM_MAMMARY_STEM_CELL_UP | 24 | 1.5144 | FRE21 |
| BLALOCK_ALZHEIMERS_DISEASE_DN | 43 | 1.5142 | MRE21 |
| DODD_NASOPHARYNGEAL_CARCINOMA_UP | 34 | 1.5125 | MRE21 |
| BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING | 20 | 1.5116 | FPE21 |
| KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_UP | 33 | 1.5063 | MRE21 |
| SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP | 22 | 1.5058 | MRE21 |
| DANG_BOUND_BY_MYC | 42 | 1.5048 | MRE21 |
| KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_UP | 27 | 1.5014 | MRE21 |
GSEA categories with absolute NES (Abs NES) scores greater than 1.5.